Merck & Company Inc (MRK)vsRapport Therapeutics, Inc. Common Stock (RAPP)
MRK
Merck & Company Inc
$120.79
-1.42%
HEALTHCARE · Cap: $285.64B
RAPP
Rapport Therapeutics, Inc. Common Stock
$36.10
-3.71%
HEALTHCARE · Cap: $1.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 328740% more annual revenue ($65.77B vs $20.00M). MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
RAPP
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Intrinsic value data unavailable for RAPP.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : RAPP
The strongest argument for RAPP centers on Debt/Equity, Altman Z-Score.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : RAPP
The primary concerns for RAPP are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (50/100 vs 25/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Rapport Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Rapport Therapeutics, Inc. is an innovative biotechnology firm focused on creating transformative therapeutics for neurodegenerative diseases, particularly Alzheimer's disease and associated cognitive disorders. Leveraging proprietary drug candidates and advanced technology platforms, the company aims to push the frontiers of neuroscience through rigorous scientific research and clinical validation. By addressing critical unmet medical needs, Rapport Therapeutics is well-positioned to contribute to meaningful advancements in treatment options, thereby offering hope to patients suffering from debilitating cognitive impairments.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?